By SPC News Staff
The FDA has expanded the indication for lenalidomide (Revlimid, Celgene) to include use for patients with multiple myeloma as maintenance therapy following autologous hematopoietic stem cell transplant (auto-HSCT).
The expanded indication makes lenalidomide the first and only treatment to receive FDA approval for maintenance use following auto-HSCT.